Immune Modulation of Monocytes Dampens the IL-17

Animals Antigens, Ly / metabolism Disease Models, Animal Humans Imiquimod / administration & dosage Immunologic Factors / pharmacology Interleukin-17 / metabolism Interleukin-1beta / metabolism Interleukin-23 / metabolism Intraepithelial Lymphocytes / immunology Macrophages / immunology Male Mice Monocytes / drug effects Psoriasis / chemically induced Severity of Illness Index Skin / cytology

Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
12 2020
Historique:
received: 09 01 2020
revised: 12 03 2020
accepted: 17 03 2020
pubmed: 12 5 2020
medline: 2 4 2021
entrez: 12 5 2020
Statut: ppublish

Résumé

Psoriasis is a chronic inflammatory autoimmune skin condition that affects millions of people worldwide. It is driven by IL-17-producing CD4 and γδ T cells and targeted by current anti-IL-17 or anti-IL-23 mAb therapies. These treatments are expensive, increase the risk of opportunistic infections, and do not specifically target the inflammatory cascade. Other cells, including inflammatory monocytes, have been shown to migrate to psoriatic plaques in both human disease and the imiquimod-induced mouse model and could thus constitute potential alternative therapeutic targets. In the mouse, immune modifying particles (IMPs) specifically target Ly6C

Identifiants

DOI: 10.1016/j.jid.2020.03.973 PMID: 32389535
pubmed: 32389535
pii: S0022-202X(20)31456-1
doi: 10.1016/j.jid.2020.03.973
pii:
doi:

Substances chimiques

Antigens, Ly 0
IL1B protein, mouse 0
Immunologic Factors 0
Interleukin-17 0
Interleukin-1beta 0
Interleukin-23 0
Ly-6C antigen, mouse 0
Imiquimod P1QW714R7M

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2398-2407.e1

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Gabriela V Pinget (GV)

Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, New South Wales, Australia.

Jian Tan (J)

Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, New South Wales, Australia; Human Health, Nuclear Science & Technology and Landmark Infrastructure (NSTLI), Australian Nuclear Science and Technology Organisation, Sydney, New South Wales, Australia.

Paula Niewold (P)

Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, New South Wales, Australia.

Eugenia Mazur (E)

Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, New South Wales, Australia.

Alexandra S Angelatos (AS)

Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, New South Wales, Australia.

Nicholas J C King (NJC)

Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, New South Wales, Australia; Sydney Cytometry, The University of Sydney and The Centenary Institute, Camperdown, New South Wales, Australia.

Laurence Macia (L)

Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, New South Wales, Australia. Electronic address: laurence.macia@sydney.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes Ly › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Aminoquinoléines › Imiquimod › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Interleukine-17 › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Monokines › Interleukine-1 › Interleukine-1 bêta › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Interleukine-23 › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Lymphocytes intra-épithéliaux › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Macrophages › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Monocytes › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Dermatoses papulosquameuses › Psoriasis › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes de santé › Indicateurs d'état de santé › Acuité des besoins du patient › Indice de gravité de la maladie › Immune Modulation of Monocytes Dampens the IL-17
questionsmedicales.fr › Système tégumentaire › Peau › Immune Modulation of Monocytes Dampens the IL-17